Baoyan Bai, June Helen Myklebust and Sébastien Wälchli just published a protocol on how to edit B cell lymphoma using CRISPR/Cas9 technology, make sure to have a look here!
Sébastien Wälchli and Mouldy Sioud published also a protocol on CRISPR/Cas9 as a tool for adoptive cell therapy. More information here!
Finally, Nicholas Casey published recently a paper on the use of RNAi with TCR transfer to enhance safety and efficiency. Follow the guide!
Vestre K, Persiconi I, Distefano MB, Mensali N, Guadagno NA, Bretou M, Wälchli S, Arnold-Schrauf C, Bakke O, Dalod M, Lennon-Dumenil AM, Progida C(2021) Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton J Cell Sci(in press) DOI 10.1242/jcs.259221, PubMed 34494097
Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, Wälchli S(2021) "Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms FASEB J, 35(9), e21750 DOI 10.1096/fj.202100025R, PubMed 34424568
Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM(2021) Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors Oncoimmunology, 10(1), 1936757 DOI 10.1080/2162402X.2021.1936757, PubMed 34235003